Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paraoxonase and atherosclerosis.

P N Durrington1, B Mackness, M I Mackness

  • 1University of Manchester Department of Medicine, Manchester Royal Infirmary, Manchester, England. pdurrington@hq.cmht.nwest.nhs.uk

Arteriosclerosis, Thrombosis, and Vascular Biology
|April 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): A retrospective cohort study of individuals with FH in UK primary care and the UK Simon Broome register, linked with national hospital records.

Atherosclerosis·2025
Same author

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.

Atherosclerosis·2018
Same author

The antioxidant properties of high-density lipoproteins in atherosclerosis.

Panminerva medica·2012
Same author

The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease.

Current molecular medicine·2011
Same author

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

European journal of preventive cardiology·2011
Same author

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).

Diabetic medicine : a journal of the British Diabetic Association·2010

High density lipoprotein (HDL) antioxidant activity, primarily from paraoxonase-1 (PON1), shows potential in preventing atherosclerosis. Low serum PON1 activity is linked to coronary heart disease, suggesting therapeutic targets.

Area of Science:

  • Cardiovascular Research
  • Biochemistry
  • Atherosclerosis

Background:

  • High density lipoprotein (HDL) possesses antioxidant properties crucial for cardiovascular health.
  • Paraoxonase-1 (PON1) is the primary enzyme responsible for HDL's antioxidant activity.
  • Oxidative modification of low density lipoprotein (LDL) is a key factor in atherogenesis.

Purpose of the Study:

  • To investigate the role of PON1 in protecting against atherogenesis.
  • To explore the association between PON1 genetic polymorphisms and coronary heart disease (CHD).
  • To determine if low serum PON1 activity is a risk factor for CHD.

Main Methods:

  • Experiments utilizing transgenic PON1 knockout mice.
  • Analysis of genetic polymorphisms in PON1.

Related Experiment Videos

  • Case-control studies examining serum PON1 activity and CHD incidence.

    • Main Results:

    • Transgenic PON1 knockout mice studies suggest PON1 protects against atherogenesis.
    • Certain PON1 polymorphisms, less effective at preventing LDL lipid peroxidation, are overrepresented in CHD patients, especially with diabetes.
    • Preliminary evidence indicates a positive association between low serum PON1 activity and CHD.

    Conclusions:

    • PON1 plays a significant role in the atheroprotective effects of HDL.
    • PON1 genetic variations and reduced serum activity are associated with increased risk of coronary heart disease.
    • Modulating serum PON1 activity presents a potential therapeutic strategy for testing the oxidant model of atherosclerosis.